Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Печать: 2151-8017
ISSN Онлайн: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2016017273
pages 119-126

KLF4 in Ovarian Cancer

Junming Yue
Department of Pathology and Laboratory Medicine and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163
Baojin Wang
The Third Affiliated Hospital, Zhengzhou University, China
Ziyun Du
Department of Pathology and Laboratory Medicine and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163
Lawrence M. Pfeffer
Department of Pathology and Laboratory Medicine and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163

Краткое описание

The Kruppel-like factor 4 (KLF4) transcriptional factor functions as a tumor suppressor or oncogene in different human cancers. Ovarian cancer is one of the most aggressive malignancies in women. In this review, we discuss the role of KLF4 and the KLF4 regulatory network in ovarian cancer. KLF4 expression inhibits ovarian cancer cell proliferation, migration, invasion, and metastasis. KLF4 inhibits the epithelial-to-mesenchymal transition by directly binding to the promoter of E-cadherin in ovarian cancer cells. Moreover, KLF4 inhibits the cancer stem cell phenotype in ovarian cancer. KLF4 not only regulates microRNA expression but is also targeted by microRNAs. It is a potential biomarker for prognosis and drug targeting in ovarian cancer and may contribute to ovarian cancer metastasis and chemoresistance through a complex gene regulatory network.

Ключевые слова: EMT, KLF4, ovarian cancer

Articles with similar content:

Bifunctional Role of Kruppel-Like Factor 4 in Hematological Malignancies
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Sara Huerta-Yepez, Otoniel Martinez-Maza, Mario I. Vega, Liliana Moreno Vargas, Luz A. Franco-Cea, Mario Morales-Martinez
RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-κB/Snail/YY1/RKIP Resistance-Driver Loop
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 6
Benjamin Bonavida
Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 4
R. S. R. Murthy, Suresh P. Vyas, Manish K. Gupta, Sahil Aggarwal, Swati Gupta
The Activated NF-κB-Snail-RKIP Circuitry in Cancer Regulates Both the Metastatic Cascade and Resistance to Apoptosis by Cytotoxic Drugs
Critical Reviews™ in Immunology, Vol.29, 2009, issue 3
Katherine Wu, Benjamin Bonavida
Epigenetic/Genetic Mismatch: Using Transdifferentiation as a Potential Cancer Therapy to Exploit the Cell Type Specificity of Cancer
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Devasis Chatterjee, Andrew R. Mendelsohn, Jennifer L. Lei